Author: Kathryn Atkins

Figure 4: Depletion of DHX33 antagonizes GPS167-mediated cytotoxicity.

Anticancer Potential of CLK Kinase Inhibitors 1C8 and GPS167 via EMT and Antiviral Immune Response

May 20, 2024

“[...] we have characterized a pair of compounds that impact multiple processes that are relevant to cancer cell proliferation but also, and possibly more importantly, to metastasis [...].” BUFFALO, NY-… read more

Figure 1: Cyclin D1 protein expression by immunohistochemistry in histological sections.

Oncotarget

Cyclin D1 Expression in Penile Cancer

May 15, 2024

“Brazil holds the global record for penile cancer incidence.” BUFFALO, NY- May 15, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 14, 2024, entitled,… read more

Oncotarget

Oncotarget at SSP 46th Annual Meeting

May 13, 2024

Oncotarget is proud to participate at the Society for Scholarly Publishing (SSP) 46th Annual Meeting from May 29–31, 2024, in Boston, Massachusetts. BUFFALO, NY- May 13, 2024 – Impact Journals… read more

Figure 5: AI-generated PET results shown overlaid on CT.

Oncotarget

Deep Learning-based Whole-body Prostate-specific Membrane Antigen PET/CT Attenuation Correction

May 8, 2024

“We have developed a Pix-2-Pix GAN model to perform attenuation correction on whole-body PSMA [prostate-specific membrane antigen] PET images with 18F-DCFPyL.” BUFFALO, NY- May 8, 2024 – A new research… read more

Figure 4: The effect of SARS-CoV-2 spike on cell growth and death.

Oncotarget

Transfected SARS-CoV-2 Spike DNA Suppresses Cancer Cell Response to Chemotherapy

May 6, 2024

“Our findings have implications for the natural history of prolonged or repeated SARS-CoV-2 infection as well as design of anti-COVID-19 vaccines that are administered repeatedly as booster shots.” BUFFALO, NY-… read more

Oncotarget

Oncotarget Sponsors 19th International p53 Workshop in Italy

April 29, 2024

Oncotarget is a contributing sponsor at the 19th International p53 Workshop in Trieste, Italy, on May 13–16, 2024. BUFFALO, NY- April 29, 2024 – Oncotarget is a contributing sponsor at… read more

Figure 7: B-cell depletion of BTA106 in cynomolgus monkeys.

Oncotarget

Novel Therapeutic Bispecific Antibodies for B-cell Lymphoma

April 16, 2024

“Our results indicate that IgM-dependent bispecific antibodies are potent therapeutic agents for B-cell malignancies.” BUFFALO, NY- April 16, 2024 – A new research paper was published in Oncotarget's Volume 15… read more

Figure 2: Effect of treatment with MIA-602 on the growth of Doxorubicin-resistant K-562 tumors xenographed into nude mice.

Oncotarget

Exploring the Role of MIA-602 in Overcoming Doxorubicin-resistance in Acute Myeloid Leukemia

April 10, 2024

“Our results reveal that MIA-602 may be a useful treatment for Doxorubicin-resistant AML [...]” BUFFALO, NY- April 10, 2024 – A new research paper was published in Oncotarget's Volume 15… read more

Figure 2: Analysis of immune cell subsets during neoadjuvant therapy.

Oncotarget

Durvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast Cancer

March 27, 2024

“[...] this trial was stopped early after 3 of the first 8 enrolled patients experienced immunotherapy-related toxicity or suspected disease progression [...]” BUFFALO, NY- March 27, 2024 – A new… read more

Figure 6: Effects of various drug combinations on molecular markers of apoptosis in patient-derived cell samples.

Oncotarget

ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells

March 25, 2024

“[...] the combination of ABT199/venetoclax and Thio enhances the cytotoxicity of (Flu+Clad+Bu) in AML cell lines and leukemia patient-derived cell samples.” BUFFALO, NY- March 25, 2024 – A new research… read more